A randomised feasibility/phase II study (SBG 2004-1) with dose-dense/tailored epirubicin, cyclophoshamide (EC) followed by docetaxel (T) or fixed dosed dose-dense EC/T versus T, doxorubicin and C (TAC) in node-positive breast cancer

Acta Oncologica

Volumn 50, Issue 1, 2011, Pages 35-41

  Margolin, Sara ^a   Bengtsson, Nils Olof ^b   Carlsson, Lena ^c   Edlund, Per ^d   Hellström, Mats ^a   Karlsson, Per ^e   Lidbrink, Elisabet ^a   Linderholm, Barbro ^f   Lindman, Henrik ^g   Malmström, Per ^h   Pettersson Skölld, Dagny ^a   Söderberg, Martin ^h   Villman, Kenneth ⁱ   Bergh, Jonas ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UMEÅ UNIVERSITY HOSPITAL   (Sweden)

^c SUNDSVALL HOSPITAL   (Sweden)

^d Gävle Hopsital ^*  (Sweden)

^e SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^f LINKÖPING UNIVERSITY HOSPITAL   (Sweden)

^g UPPSALA UNIVERSITY HOSPITAL   (Sweden)

^h LUND UNIVERSITY HOSPITAL   (Sweden)

ⁱ ÖREBRO UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

CIPROFLOXACIN; CYCLOPHOSPHAMIDE; DOCETAXEL; EPIRUBICIN; MESNA; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; SEROTONIN 3 ANTAGONIST; STEROID;

ADULT; AGED; ANOREXIA; ANTICIPATORY NAUSEA AND VOMITING; ARTICLE; BREAST CANCER; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG FATALITY; DRUG SAFETY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FOLLOW UP; HAND FOOT SYNDROME; HOSPITALIZATION; HUMAN; INFECTION; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MUSCULOSKELETAL PAIN; MYALGIA; NAUSEA; NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 78650551401     PISSN: 0284186X     EISSN: 1651226X     Source Type: Journal    
DOI: 10.3109/0284186X.2010.535847     Document Type: Article

References (25)

1. Clarke M, Coates AS, Darby SC, Davies C, Gelber RD, Godwin J, et al. Adjuvant chemotherapy in oestrogenreceptor- poor breast cancer: Patient-level meta-analysis of randomised trials. Lancet 2008;371(9606):29-40.
2. Polychemotherapy for early breast cancer: An overview of the randomised trials. Early Breast Cancer Trialists ' Collaborative Group. Lancet 1998;352(9132):930-42.
3. Levine MN, Pritchard KI, Bramwell VH, Shepherd LE, Tu D, Paul N. Randomized trial comparing cyclophosphamide, epirubicin, and fl uorouracil with cyclophosphamide, methotrexate, and fl uorouracil in premenopausal women with node-positive breast cancer: Update of National Cancer Institute of Canada Clinical Trials Group Trial MA5. J Clin Oncol 2005;23:5166-70. (Pubitemid 46224025)
4. Martin M, Pienkowski T, Mackey J, Pawlicki M, Guastalla JP, Weaver C, et al. Adjuvant docetaxel for node-positive breast cancer. N Engl J Med 2005;352:2302-13. (Pubitemid 40740554)
5. Roche H, Fumoleau P, Spielmann M, Canon JL, Delozier T, Serin D, et al. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: The FNCLCC PACS 01 Trial. J Clin Oncol 2006;24: 5664-71. (Pubitemid 46631307)
6. Jones SE, Savin MA, Holmes FA, O'Shaughnessy JA, Blum JL, Vukelja S, et al. Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer. J Clin Oncol 2006;24:5381-7. (Pubitemid 46623169)
7. Ferguson T, Wilcken N, Vagg R, Ghersi D, Nowak AK. Taxanes for adjuvant treatment of early breast cancer. Cochrane Database Syst Rev 2007(4):CD004421. (Pubitemid 46755374)
8. Martin M, Rodriguez-Lescure A, Ruiz A, Alba E, Calvo L, Ruiz- Borrego M, et al. Randomized phase 3 trial of fl uorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer. J Natl Cancer Inst 2008;100:805-14. (Pubitemid 351809668)
9. Sandstrom M, Freijs A, Larsson R, Nygren P, Fjallskog ML, Bergh J, et al. Lack of relationship between systemic exposure for the component drug of the fl uorouracil, epirubicin, and 4-hydroxycyclophosphamide regimen in breast cancer patients. J Clin Oncol 1996;14:1581-8. (Pubitemid 26134217)
10. Wilking N, Lidbrink E, Wiklund T, Erikstein B, Lindman H, Malmstrom P, et al. Long-term follow-up of the SBG 9401 study comparing tailored FEC-based therapy versus marrowsupported high-dose therapy. Ann Oncol 2007;18:694-700. (Pubitemid 46523273)
11. Bonnefoi HR, Bogaerts J, Piccart M, Mauriac L, Fumoleau P, Jassem J, et al. Phase III trial (EORTC 10994/BIG 00-01) assessing the value of p53 using a functional assay to predict sensitivity to a taxane versus nontaxane primary chemotherapy in breast cancer: Final analysis. In: 2010 ASCO Annual Meeting; 2010. J Clin Oncol 28:18s, 2010 (suppl; abstr LBA503); 2010.
12. Citron ML, Berry DA, Cirrincione C, Hudis C, Winer EP, Gradishar WJ, et al. Randomized trial of dose-dense versus conventionally scheduled and sequential versus concurrent combination chemotherapy as postoperative adjuvant treatment of node-positive primary breast cancer: First report of Intergroup Trial C9741/Cancer and Leukemia Group B Trial 9741. J Clin Oncol 2003;21:1431-9. (Pubitemid 46594092)
13. Moebus V, Jackisch C, Lueck HJ, du Bois A, Thomssen C, Kurbacher C, et al. Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: Mature results of an AGO phase III study. J Clin Oncol 2010;28:2874-80.
14. P iedbois P, Serin D, Priou F, Laplaige P, Greget S, Angellier E, et al. Dose-dense adjuvant chemotherapy in node-positive breast cancer: Docetaxel followed by epirubicin/ cyclophosphamide (T/EC), or the reverse sequence (EC/T), every 2 weeks, versus docetaxel, epirubicin and cyclophosphamide (TEC) every 3 weeks. AERO B03 randomized phase II study. Ann Oncol 2007;18:52-7. (Pubitemid 46152499)
15. Di Leo A, Crown J, Nogaret JM, Duffy K, Bartholomeus S, Dolci S, et al. A feasibility study evaluating docetaxel-based sequential and combination regimens in the adjuvant therapy of node-positive breast cancer. Ann Oncol 2000;11:169-75. (Pubitemid 30148730)
16. Schwartz J, Domchek SM, Hwang WT, Fox K. Evaluation of anemia, neutropenia and skin toxicities in standard or dose-dense doxorubicin/ cyclophosphamide (AC)-paclitaxel or docetaxel adjuvant chemotherapy in breast cancer. Ann Oncol 2005;16:247-52. (Pubitemid 40309304)
17. Wildiers H, Forceville K, Paridaens R, Joensuu H. Taxanes and anthracyclines in early breast cancer: Which fi rst? Lancet Oncol 2010;11:219-20.
18. Budman DR, Berry DA, Cirrincione CT, Henderson IC, Wood WC, Weiss RB, et al. Dose and dose intensity as determinants of outcome in the adjuvant treatment of breast cancer. The Cancer and Leukemia Group B. J Natl Cancer Inst 1998;90:1205-11.
19. Cameron DA, Massie C, Kerr G, Leonard RC. Moderate neutropenia with adjuvant CMF confers improved survival in early breast cancer. Br J Cancer 2003;89:1837-42. (Pubitemid 37533256)
20. Poikonen P, Saarto T, Lundin J, Joensuu H, Blomqvist C. Leucocyte nadir as a marker for chemotherapy Efficacy in node-positive breast cancer treated with adjuvant CMF. Br J Cancer 1999;80:1763-6. (Pubitemid 29389629)
21. Saarto T, Blomqvist C, Rissanen P, Auvinen A, Elomaa I. Haematological toxicity: A marker of adjuvant chemotherapy Efficacy in stage II and III breast cancer. Br J Cancer 1997;75:301-5. (Pubitemid 27019578)
22. Wacker B, Nagrani T, Weinberg J, Witt K, Clark G, Cagnoni PJ. Correlation between development of rash and Efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res 2007;13:3913-21. (Pubitemid 47037599)
23. Tejpar S, Peeters M, Humblet Y, Vermorken JB, De Hertogh G, De Roock W, et al. Relationship of Efficacy with KRAS status (wild type versus mutant) in patients with irinotecanrefractory metastatic colorectal cancer (mCRC), treated with irinotecan (q2w) and escalating doses of cetuximab (q1w): The EVEREST experience (preliminary data). In: ASCO; 2008: JCO; 2008. p. Abstract 4001.
24. Cuzick J, Sestak I, Cella D, Fallowfi eld L. Treatmentemergent endocrine symptoms and the risk of breast cancer recurrence: A retrospective analysis of the ATAC trial. Lancet Oncol 2008;9:1143-8.
25. Dang CT, D'Andrea GM, Moynahan ME, Dickler MN, Seidman AD, Fornier M, et al. Phase II study of feasibility of dose-dense FEC followed by alternating weekly taxanes in high-risk, four or more node-positive breast cancer. Clin Cancer Res 2004;10:5754-61. (Pubitemid 39180952)